Limited-Stage Small Cell Lung Cancer
Conditions
Interventions
None listed
Sponsors
Kitagawa Hiroshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with LS-SCLC pathologically diagnosed by tissue or cytology between January 2014 and December 2020 2. Patients provided written informed consent, in cases where obtaining informed consent is not difficult, or appropriate opt out approach was taken for this study 3. Patient aged 18 years or older at the time of diagnosis of LS-SCLC 4. Patient with access to accurate data from medical records by PIs judgment
Exclusion criteria
Exclusion criteria: 1. Patients participating in clinical trials during the observation period of the study 2. Patients who received surgery or only radiation therapy (including SBRT) as 1L treatment for LS-SCLC, and who received no treatment or only best supportive care (BSC) without active treatment for LS-SCLC
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Median OS with each 95 percent confidence interval (CI) from the start of 1L treatment in FAS and in each 1L treatment cohort | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Median rwPFS with each 95 percent CI from the start of 1L treatment in FAS and in each 1L treatment cohort 2. Proportion of each treatment pattern (cCRT, sCRT, CT alone) in each 1L treatment cohort 3. Median rwPFS and OS with each 95% CI from the start of each 1L treatment for aged subgroup in each 1L treatment cohort 4. Proportion of recurrence pattern after 1L therapy (Local recurrence, distant metastasis without brain metastasis, or distant metastasis with brain metastasis) in each 1L treatment cohort 5. Proportion of rwTR (CR/PR/SD/PD/NE) in each 1L treatment cohort 6. Proportion of incidence of AEs associated with cCRT and sCRT in cCRT and sCRT cohort | — |
Contacts
Public ContactKawai Daisuke
AstraZeneca K.K.
Outcome results
None listed